Walleye Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Walleye Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-57,200	Closed	-$6.62M	–	5810
2023 Q3	$6.62M	Buy	57,200 +56,100	+5,100%	+$6.03M	0.02%	844
2023 Q2	$113K	Sell	1,100 -400	-27%	-$42.2K	﹤0.01%	3382
2023 Q1	$164K	Hold	1,500	–	–	﹤0.01%	2620
2022 Q4	$171K	Buy	+1,500	New	+$125K	﹤0.01%	2137
2020 Q1	–	Sell	-500	Closed	-$18K	–	2052
2019 Q4	$18K	Sell	500 -24,000	-98%	-$736K	﹤0.01%	1616
2019 Q3	$667K	Buy	24,500 +4,400	+22%	+$114K	0.04%	614
2019 Q2	$484K	Buy	20,100 +7,200	+56%	+$183K	0.05%	504
2019 Q1	$341K	Buy	+12,900	New	+$306K	0.06%	546

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Walleye Capital's HZNP Position: Q3 2023 in Review

Walleye Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 45,055 shares — an estimated $4.84M sold.

Walleye Capital first reported a position in HZNP in Q1 2019 and held it in 10 quarters. The position peaked at $6.41M in Q1 2023. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Walleye Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Walleye Capital sold 45,055 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $4.84M.
Walleye Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 10 quarters.
Walleye Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6.41M in Q1 2023.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Walleye Capital's 13F filing for Q3 2023, filed 14 Nov 2023.